Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment

Table 1 Baseline characteristics of patients in Groups A, B, and C

	Group A (n = 41)	Group B (n = 30)	Group C (n = 63)	P value
Age (yr)	70 (43–89)	67 (41–87)	69 (48–87)	0.233
Sex
Male, n (%)	33 (80.5)	22 (73.3)	44 (69.8)	0.481
Child-Pugh class, n (%)				0.288
A	33 (80.5)	27 (90.0)	57 (90.5)
B	8 (19.5)	3 (10.0)	6 (9.5)
Etiology, n (%)
HCV	22 (53.7)	11 (36.7)	44 (69.8)	0.235
HBV	9 (21.9)	10 (33.3)	11 (17.5)	0.417
Other	10 (24.4)	9 (30.0)	8 (12.7)	0.109
Portal vein thrombosis	14 (34.1)	10 (33.3)	11 (17.5)	0.099
Extrahepatic spread, n (%)	20 (48.8)	19 (63.3)	28 (44.4)	0.230
AFP (ng/mL), n (%)
> 400	17 (41.5)	17 (56.7)	29 (46.0)	0.437
BCLC staging, n (%)				0.333
Stage B	15 (36.6)	10 (33.3)	30 (47.6)
Stage C	26 (63.4)	20 (66.7%)	33 (52.4)
ECOG performance status, n (%)				0.955
0	30 (75.6)	22 (73.3)	46 (73.0)
1	10 (24.4)	8 (26.7)	17 (27.0)
Total bilirubin (mg/dL)	0.99 ± 0.36	0.91 ± 0.37	0.83 ± 0.33	0.052
Albumin (g/L)	3.61 ± 0.50	3.73 ± 0.54	3.82 ± 0.49	0.301
INR	1.14 ± 0.11	1.15 ± 0.16	1.14 ± 0.19	0.481
Pre-sorafenib TACE procedures, n (%)				0.531
0	13 (31.7)	9 (30.0)	20 (31.8)
1	3 (7.3)	6 (20.0)	13 (20.6)
2	6 (14.6)	1 (3.3)	4 (6.4)
3	4 (9.8)	2 (6.7)	8 (12.7)
4	5 (12.2)	3 (10.0)	12 (19.0)
> 5	10 (24.4)	9 (30.0)	6 (9.5)

AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; HCV: Hepatitis C virus; HBV: Hepatitis B virus; INR: International normalized ratio; TACE: Transcatheter arterial chemoembolization; ECOG: Eastern Cooperative Oncology Group.